BSE Live
Mar 13, 16:01Prev. Close
4697.50
Open Price
4651.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:49Prev. Close
4695.00
Open Price
4686.00
Bid Price (Qty.)
4623.00 (15)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Pfizer (in Rs. Cr.) | Nov 08 | Nov 07 | Nov 06 | |
| Per Share Ratios | ||||
| Basic EPS (Rs.) | 100.38 | 113.93 | 35.63 | |
| Diluted EPS (Rs.) | 100.38 | 113.93 | 35.63 | |
| Cash EPS (Rs.) | 104.11 | 117.14 | 40.01 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 301.94 | 217.71 | 135.95 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 301.94 | 217.71 | 135.95 | |
| Revenue from Operations/Share (Rs.) | 245.68 | 246.49 | 245.85 | |
| PBDIT/Share (Rs.) | 73.20 | 159.62 | 66.73 | |
| PBIT/Share (Rs.) | 69.47 | 156.41 | 62.35 | |
| PBT/Share (Rs.) | 69.47 | 156.41 | 62.33 | |
| Net Profit/Share (Rs.) | 100.38 | 113.93 | 35.63 | |
| NP After MI And SOA / Share (Rs.) | 100.38 | 113.93 | 35.63 | |
| Profitability Ratios | ||||
| PBDIT Margin (%) | 29.79 | 64.75 | 27.14 | |
| PBIT Margin (%) | 28.27 | 63.45 | 25.36 | |
| PBT Margin (%) | 28.27 | 63.45 | 25.35 | |
| Net Profit Margin (%) | 40.85 | 46.22 | 14.49 | |
| NP After MI And SOA Margin (%) | 40.85 | 46.22 | 14.49 | |
| Return on Networth/Equity (%) | 33.24 | 52.33 | 26.20 | |
| Return on Capital Employed (%) | 33.13 | 51.97 | 26.06 | |
| Return on Assets (%) | 27.21 | 38.99 | 16.40 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 66.61 | 84.36 | 113.19 | |
| Liquidity Ratios | ||||
| Current Ratio (X) | 5.04 | 3.59 | 2.30 | |
| Quick Ratio (X) | 4.41 | 3.14 | 1.88 | |
| Inventory Turnover Ratio (X) | 5.87 | 7.67 | 7.39 | |
| Dividend Payout Ratio (NP) (%) | 12.45 | 24.13 | 63.14 | |
| Dividend Payout Ratio (CP) (%) | 12.00 | 23.47 | 56.23 | |
| Earnings Retention Ratio (%) | 87.55 | 75.87 | 36.86 | |
| Cash Earnings Retention Ratio (%) | 88.00 | 76.53 | 43.77 | |
| Coverage Ratios | ||||
| Interest Coverage Ratios (%) | -- | 30,709.18 | 2,602.58 | |
| Interest Coverage Ratios (Post Tax) (%) | -- | 30,709.18 | 2,602.58 | |
| Valuation Ratios | ||||
| Enterprise Value (Cr.) | 851.37 | 1,451.84 | 2,003.96 | |
| EV/Net Operating Revenue (X) | 1.16 | 1.97 | 2.73 | |
| EV/EBITDA (X) | 3.90 | 3.05 | 10.06 | |
| MarketCap/Net Operating Revenue (X) | 1.90 | 2.63 | 3.15 | |
| Retention Ratios (%) | 87.54 | 75.86 | 36.85 | |
| Price/BV (X) | 1.55 | 2.97 | 5.70 | |
| Price/Net Operating Revenue | 1.90 | 2.63 | 3.15 | |
| Earnings Yield | 0.21 | 0.18 | 0.05 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth